Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.53
0.00 (0.00%)
At close: Jun 26, 2026, 4:00 PM EDT
9.52
-0.01 (-0.10%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Immatics Revenue
Immatics had revenue of 7.61M EUR in the quarter ending March 31, 2026, a decrease of -59.04%. This brings the company's revenue in the last twelve months to 37.30M, down -74.13% year-over-year. In the year 2025, Immatics had annual revenue of 48.27M, down -69.03%.
Revenue (ttm)
37.30M EUR
Revenue Growth
-74.13%
P/S Ratio
30.26
Revenue / Employee
55,010 EUR
Employees
678
Market Cap
1.30B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.27M | -107.57M | -69.03% |
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
| Dec 31, 2019 | 18.45M | 14.68M | 389.36% |
| Dec 31, 2018 | 3.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| MannKind | 360.78M |
| Ascentage Pharma Group International | 82.08M |
| EyePoint | 7.61M |
| Inhibrx Biosciences | 1.30M |
IMTX News
- 27 days ago - Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - GlobeNewsWire
- 27 days ago - Immatics announces presentation of extended data from Phase 1 trial of IMA401 - TheFly
- 27 days ago - Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy - TheFly
- 4 weeks ago - Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer - GlobeNewsWire
- 4 weeks ago - Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Immatics reports Q1 EPS (43c), consensus (44c) - TheFly
- 6 weeks ago - Immatics Announces First Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Immatics Earnings release: Q1 2026 - Filings